Cynvec is a preclinical company built upon the oncolytic Sindbis virus platform that has been developed at Prof. Daniel Meruelo’s laboratory at the NYU Medical School.   The Company holds an exclusive license for the platform from New York University (NYU).  Cynvec is financed by a group of New York-based investors with a vision of supporting the development of effective cancer immunotherapies that could benefit all cancer patients and manage metastatic cancers.  The company conducts its research through Prof. Meruelo’s lab and outsources the product development to seasoned consulting firms, contract manufacturing organizations (CMOs) and contract research organizations (CROs).